A more Tubulocentric View of Diabetic Kidney Disease by Zeni, L et al.
Vol.:(0123456789) 
J Nephrol (2017) 30:701–717 
DOI 10.1007/s40620-017-0423-9
REVIEW
A more tubulocentric view of diabetic kidney disease
Letizia Zeni1,2,3  · Anthony G. W. Norden2 · Giovanni Cancarini1,3 · 
Robert J. Unwin2,4 
Received: 12 June 2017 / Accepted: 22 July 2017 / Published online: 24 August 2017 
© The Author(s) 2017. This article is an open access publication
considered as direct indicators of injury of the proximal 
tubule (PT), such as N-acetyl-β-D-glucosaminidase, Neu-
trophil Gelatinase-Associated Lipocalin and Kidney Injury 
Molecule-1, and other functional PT biomarkers, such as 
Urine free Retinol-Binding Protein 4 and Cystatin C, which 
reflect impaired reabsorption of filtered proteins. The clini-
cal application of these measurements to diabetic patients 
will be reviewed in the context of the need for better bio-
markers for early DN.
Keywords Diabetic kidney disease · Microalbuminuria · 
Hyperfiltration · SGLT2 nephro-protection · Diabetic 
tubulopathy · Tubular biomakers
Abbreviations
ATP  Adenosine triphosphate
AGEs  Advanced glycosylation end 
products
ACR  Albumin:creatinine ratio
FITC-albumin  Albumin-fluorescein isothiocy-
anate conjugate
ALP  Alkaline phosphatase
AT1  Angiotensin II receptor type 1
BB  Brush Border
CCL-2  Chemokine (C-C motif) ligand 2
CTGF  Connective tissue growth factor
DM  Diabetes mellitus
DKD  Diabetic kidney disease
DN  Diabetic nephropathy
ESRD  End stage renal disease
FSGS  Focal segmental 
glomerulosclerosis
FTB  Functional tubular biomarkers
Gpnmb  Glycoprotein non-metastatic mela-
noma B
Abstract Diabetic nephropathy (DN) is a common compli-
cation of Diabetes Mellitus (DM) Types 1 and 2, and preven-
tion of end stage renal disease (ESRD) remains a major chal-
lenge. Despite its high prevalence, the pathogenesis of DN 
is still controversial. Initial glomerular disease manifested 
by hyperfiltration and loss of glomerular size and charge 
permselectivity may initiate a cascade of injuries, including 
tubulo-interstitial disease. Clinically, ‘microalbuminuria’ is 
still accepted as an early biomarker of glomerular damage, 
despite mounting evidence that its predictive value for DN is 
questionable, and findings that suggest the proximal tubule is 
an important link in the development of DN. The concept of 
‘diabetic tubulopathy’ has emerged from recent studies, and 
its causative role in DN is supported by clinical and experi-
mental evidence, as well as plausible pathogenetic mecha-
nisms. This review explores the ‘tubulocentric’ view of DN. 
The recent finding that inhibition of proximal tubule (PT) 
glucose transport (via SGLT2) is nephro-protective in dia-
betic patients is discussed in relation to the tubule’s potential 
role in DN. Studies with a tubulocentric view of DN have 
stimulated alternative clinical approaches to the early detec-
tion of diabetic kidney disease. There are tubular biomarkers 
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GGT  γ-Glutamyltransferase
GBM  Glomerular basement membrane
GFR  Glomerular filtration rate
GSC  Glomerular sieving coefficient
GAG  Glycosaminoglycan
GLT  Glucose transporter
H-FABP  Heart fatty acid binding protein
HIF  Hypoxia-inducible factors
ICAM-1  Intercellular adhesion molecule 1
IL-1β  Interleukin 1β
IL-6  Interleukin 6
IL-8  Interleukin 8
IFTA  Interstitial fibrosis and tubular 
atrophy
KIM-1  Kidney injury molecule-1
KLF6  Krueppel-like factor 6
L-PGDS  Lipocalin-type prostaglandin-D 
synthase
L-FABP  Liver-type fatty acid binding 
protein
MIP-3α  Macrophage inflammatory 
protein-3
miRNA  MicroRNA
MAPK  Mitogen-activated protein kinase
MW  Molecular weight
MCP-1  Monocyte chemoattractant 
protein-1
LMWP  Proteins of low molecular weight
NAG  N-acetyl-β-D glucosaminidase
NGAL  Neutrophil gelatinase-associated 
lipocalin
NO  Nitric oxide
NF-κB  Nuclear factor kappa-light-chain-
enhancer of activated B cells
8-oHdG  8-Oxo-7,8-dihydro-2-deoxyguano-
sine
8-oxodG  8-oxo-7,8-dihydro-2′-
deoxyguanosine
P2X4 purinoreceptor  P2X4R
PKC  Protein kinase C
PT  Proximal Tubule
PTECs  Proximal Tubule Epithelial Cells
PAN  Purine Amino Nucleoside
ROS  Reactive Oxygen Species
RANTES  Regulated on activation normal T 
cell expressed and secreted
RRT  Renal replacement therapy
RAS  Renin-angiotensin system
RBP4  Retinol-binding protein 4
SGK-1  Serum and glucocorticoid-regu-
lated kinase 1
STAT-1  Signal transducer and activator of 
transcription 1
SGLT  Sodium–glucose cotransporter
NHE  Sodium–hydrogen exchanger
STZ  Streptozocin
STB  Structural tubular biomarkers
TLR  Toll like receptor
TGF-β  Transforming growth factor beta
TBM  Tubular basement membrane
TGF  Tubuloglomerular feedback
TNF-α  Tumor necrosis factor-α
UACR  Urinary albumin-creatinine ratio
VEGF  Vascular endothelial growth factor
WT1  Wilms’ tumor-1
Introduction
Diabetic Nephropathy (DN) is one of the principal long-
term microvascular complications of Diabetes Mellitus 
(DM) Types 1 and 2. It remains a leading cause of End Stage 
Renal Disease (ESRD) in the United States [1] and else-
where requiring renal replacement therapy (RRT). The ris-
ing incidence and prevalence of DM worldwide [2] creates 
a pressing need for earlier diagnosis and effective treatment 
of DM and its complications, including DN.
Initially, DN is considered to be a progressive disease 
characterized by significant urinary protein excretion and 
hyperfiltration, leading eventually to renal failure. The clas-
sical model of DN divides it into two phases, incipient and 
overt, which includes five progressive stages: (1) normoal-
buminuria (<30 mg/g creatinine); (2) microalbuminuria 
(30–299 mg/g); (3) macroalbuminuria (>300 mg/g) or pro-
teinuria (>0.5 g/g); (4) estimated glomerular filtration rate 
(eGFR) <30 ml/min, irrespective of albuminuria or proteinu-
ria status; and (5) the need for renal replacement [3]. The 
main features of the earliest and evident stage 2 are microal-
buminuria and an increase in GFR, both considered markers 
of glomerular damage. However, in several studies of Type 1 
and Type 2 DM patients, many exceptions to this have been 
found. Microalbuminuria can regress (to stage 1) or remain 
unchanged, and a substantial proportion of diabetic individu-
als with decreased GFR levels are normoalbuminuric [4, 5].
There is now growing evidence that the traditional pic-
ture of DN, which is that ESRD is preceded by increasing 
albuminuria and proteinuria, does not always apply. Recent 
clinical studies have demonstrated that the ‘non-albuminuric 
phenotype’ is now becoming the predominant mode of DN 
presentation [6, 7]. While renin-angiotensin system (RAS) 
inhibitors have been shown to have an important action in 
reducing urinary albumin excretion, a positive response is 
not universal, and their effect may still depend more on small 
decreases in blood pressure and GFR. Therefore, perhaps 
there is another facet of nephron function, together with 
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glomerular hemodynamics and the filtration barrier, that 
has a part to play in the pathophysiology of DN?
Indeed, recent findings have changed our overall con-
cept of DN, reflected in the newer term of ‘Diabetic Kidney 
Disease’ (DKD) [8]. As a result of emerging evidence sup-
porting a role for tubular involvement in DKD, interest has 
shifted to the proximal tubule (PT), which may play a role 
as an initiator, driver or contributor in the early pathogenesis 
of diabetes affecting the kidney.
We have conducted a literature review, firstly to address 
the questions of how the proximal tubule might interact 
with the glomerulus in early stages of DKD, and secondly 
to explore the evidence supporting a tubular role in initiating 
and/or amplifying renal damage due to DM, and lastly to 
determine which tubular biomarkers can potentially be used 
for the clinical care and follow-up of patients with diabetes. 
This review is not an argument against a central role for the 
glomerular filtration barrier or the strong evidence support-
ing early glomerular damage, but rather it is intended to 
highlight theories and evidence for PT involvement in DKD.
Although the term ‘microalbuminuria’ is widely used 
throughout the text, we recognize that it is potentially mis-
leading. In fact, there is a continuum in the relationship 
between albuminuria and the risk of renal and cardiovas-
cular disease, and the concept of a threshold level to define 
normality should be viewed with some caution [9].
Microalbuminuria and hyperfiltration: an early 
tubular contribution to their development 
and a two‑way interaction between glomerulus 
and tubule?
Microalbuminuria, a well-known marker of loss of size and 
charge permselectivity at the glomerulus [10], together with 
glomerular hyperfiltration, defined as a supraphysiologic 
increase in whole kidney GFR [11], highlight structural and 
functional changes of the glomerulus in early DKD. While 
it is often difficult to know what constitutes relative hyperfil-
tration in many Type 2 diabetics with a long history of DM 
and who come late to the attention of a nephrologist, there is 
a close interrelationship between the tubule and these clas-
sical early biomarkers of DKD.
Conventionally, the underlying mechanism of micro-
albuminuria in early stages of DN has been ascribed to 
increased glomerular filtration due to hyperfiltration or glo-
merular barrier damage, or some combination of the two. 
However, putative early involvement of the tubule, in addi-
tion to glomerular leakage, in generating microalbuminuria 
was highlighted in the late 1980s by clinical observations 
in patients with early onset Type 1 DM of relatively short 
duration [12]. A good correlation was found between urinary 
albumin excretion and markers of tubular dysfunction. Based 
on this finding, many animal models have been created to 
try to clarify the underlying mechanism. Using renal micro-
puncture and evaluation of endocytosis by Fluorescein-Iso-
Thiocyanate-(FITC)-labelled albumin, and immunoelectron 
microscopy, a Japanese group showed in 2001 that strepto-
zotocin (STZ)-induced diabetic rats had reduced reabsorp-
tion of albumin in proximal tubules (PT) compared with 
control rats. This could be partly explained by decreased 
albumin endocytosis with reduced megalin expression. Of 
importance in this study is that no increase in GFR was evi-
dent in the diabetic rats [13]. Subsequently, other groups 
found no significant difference in Glomerular Sieving Coef-
ficient (GSC) between control and insulin-dependent dia-
betic rats, despite the presence of albuminuria in the diabetic 
animals. The excess urinary albumin excretion was ascribed 
to changes in PT albumin handling, highlighting the impor-
tance of the PT in generating albuminuria [14].
Interestingly, it has been argued that the role of the PT in 
determining albuminuria in renal disorders has reduced the 
importance of defects in the glomerular barrier. According 
to this ‘retrieval hypotheisis’, normal glomeruli filter high 
levels of albumin, which appears in the urine in nephrotic 
amounts only if tubular reabsorption does not occur. This 
means that albuminuria is primarily of tubular origin [10]. 
In 2007, a study performed by Russo et al. provided new 
insights into the contribution of post-glomerular reabsorp-
tion in excretion of urinary albumin. In their work, they 
reported firstly a very much higher GSC of albumin (0.034) 
in non-proteinuric rats than previously, and secondly they 
claimed that a large amount of filtered albumin underwent 
a rapid retrieval process via transcytosis by proximal tubule 
cells (PTCs); and lastly that in rats made nephrotic by puri-
nomycin (the PAN rat model), the rate of uptake of albumin 
by the PT was decreased [15]. Although changes in the albu-
min GSC in PAN rats cannot be excluded, previous studies 
have demonstrated that for molecules of the same size as 
albumin, glomerular permeability is not altered in PAN [15, 
16]. Their estimated value for GSC in rats is much higher 
than other measurements reported in rats. Also, a study in 
humans reported a much lower estimate in normal individu-
als, namely 8 × 10−5 [17]. It has been suggested that com-
plete retrieval of the proposed amount of filtered albumin in 
rats with such high GSC would be unachievable [18].
Nevertheless, impaired tubular uptake and increased 
glomerular leakage are not mutually exclusive events [19], 
and both are potentially responsible for microalbuminuria 
in early stage DKD. Even early glomerular disease and loss 
of size and charge permselectivity in DM with increased 
albumin leakage may not cause microalbuminuria, if normal 
proximal tubular function can remove the excess albumin 
from the glomerular filtrate. Although the reserve capac-
ity for protein uptake by the PT in humans is unknown, it 
is likely that the tubule does have some spare capacity for 
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reabsorption. This suggestion is supported by the follow-
ing study in the rat. Wagner et al. demonstrated that the PT 
regulates albumin excretion rate. In their experiments, PTs 
responded to an acute exogenous overload of albumin by 
decreasing the amount of albumin retrieved; whereas after 
inducing increased endogenous albumin exposure from 
leaky glomeruli, PTs increased the proportion of albumin 
taken up. So, there is some evidence for potentially large 
reserve capacity of PTs to reabsorb filtered albumin [20]. 
Dissociation between increased glomerular leakage of albu-
min and microalbuminuria in diabetic patients has been 
suggested by several clinical studies [21, 22]. In a recent 
study of patients with Type 2 DM, an association between 
PT dysfunction and podocyte biomarkers was found, which 
was independent of the level of albuminuria and of renal 
function [22].
Dickson et al. critically re-examined the steps leading 
to uptake and metabolism of filtered albumin in the PT and 
determined which stages were interrupted [19]. They high-
lighted the complexity of protein handling throughout the 
nephron. A brief summary of the studies reporting evidence 
of proteinuria due to tubular damage in the course of DM is 
presented in Table 1.
Recent findings from animal models have provided 
evidence for a minor contribution from other parts of the 
nephron to protein reabsorption, in addition to the major 
role of megalin-cubilin-mediated endocytosis in the PT [27]. 
The amount and clinical importance of these other pathways 
remain to be determined, particularly when glomerular ultra-
structural damage and impaired PT protein uptake occur.
Regardeless of the individual contribution of either the 
glomerulus or PT to the quantity of urinary albumin excre-
tion in DKD, it has been proposed that increased protein 
leakage from the glomerulus has intrinsic renal (tubular) 
toxicity [28] that may provide a pathogenic link between 
glomerular damage and tubulo-interstitial injury in proteinu-
ric renal diseases. Protein overload due to impaired glomeru-
lar permeability causes excessive tubular protein reabsorp-
tion and abnormal protein accumulation in endolysosomes, 
which may, theoretically, up-regulate many NF-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells)-
dependent or -independent inflammatory genes (chemokines, 
cytokines and endothelin) in the PT epithelium. These are 
potentially capable of triggering an interstitial inflammatory 
reaction. Consequently, the proximal tubule has a profibrotic 
and proinflammatory role leading to synthesis and deposi-
tion of extracellular matrix, and contributing to renal scar-
ring [28]. Interestingly, Nielsen et al. have showed that in an 
FSGS (Focal Segmental GlomeruloSclerosis) mouse model, 
there is a counteracting mechanism against protein overload 
by the PT. Inflammatory mediators originating from PTECs 
during protein overload occurred early in the course of expo-
sure. However, the lysosomal system showed a well-adapted 
response to protein load by increasing synthesis of factors 
for lysosomal proteolysis. Are there any other injury sensors 
that might stimulate inflammation and fibrosis in the PT in 
response to protein overload [29]? Although the importance 
of proteinuria as a marker and driver of kidney disease has 
been examined in many proteinuric renal disorders, a study 
by Guo et al. showed, interestingly, that tubular injury is 
dependent only on the degree of podocyte damage and not 
on albuminuria per se [29, 30].
Hyperfiltration: more than a vascular effect?
Despite difficulties in a precise definition or threshold, 
increased GFR as a marker of glomerular hyperfiltration 
occurs early in the clinical course of DKD and is considered 
to be an important factor in the initiation and progression of 
kidney damage. It is thought to be due to a rise in intraglo-
merular pressure (causing barotrauma) and renal blood flow, 
resulting from an imbalance of vasoactive humoral factors 
that control pre-and post-glomerular arteriolar tone [11].
Clearly, a rise in hydrostatic pressure in the glomerulus 
may result in higher filtration pressure with an increase in 
the amount of protein passing through the glomerular bar-
rier [11]. Therefore, the amount of protein delivered to the 
PT per unit time for potential reabsorption increases with 
hyperfiltration.
As discussed in a recently published review, the patho-
genesis of glomerular hyperfiltration is complex and 
includes overlapping mechanisms, as summarized in the 
‘Tubular Theory’. This theory proposes that several tubu-
lar changes inhibit tubuloglomerular feedback (TGF). This 
negative feedback mechanism is normally controlled by 
sodium and chloride delivery to the macula densa of the 
loop of Henle. In diabetes with hyperglycemia, increased 
filtered glucose stimulates PT glucose reabsorption that 
is coupled to sodium, thereby reducing its delivery to the 
macula densa, and decreasing TGF feedback. This results in 
afferent arteriolar vasorelaxation, increased renal blood flow 
and hyperfiltration [31]. Interestingly, a study exploring the 
effect of glomerular hyperfiltration on tubular dysfunction 
reported that two markers of tubular damage (Neutrophil 
gelatinase-associated lipocalin NGAL and Kidney Injury 
Molecule-1 KIM-1) showed increased excretion in the urine 
of those with glomerular hyperfiltration and it correlated 
positively with GFR. These findings suggest that glomerular 
hyperfiltration is related to altered tubular function in DM 
patients [32].
Crucially, a study by Vallon et al. showed that inhibition 
of PT glucose reabsorption increased the amount of sodium 
delivered to the macula densa, stimulating TGF and reduc-
ing glomerular hyperfiltration, without a change in blood 
glucose concentration. The tubular hypothesis of diabetic 
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glomerular hyperfiltration suggests that the PT has a role 
in determining hyperfiltration, in addition to blood glucose 
control, through glucose reabsorption [33].
As well as increased glucose overload in the course 
of DM, parallel tubular hypertrophy and upregulation of 
sodium-glucose cotransporter 2 (SGLT2) and sodium-hydro-
gen exchange (NHE) 3 may also contribute to increasing 
hyperfiltration. Furthermore, enhanced PT reabsorption may 
reduce intratubular pressure and so increase the net pressure 
gradient for filtration across the glomerulus [11].
Understanding the relationship between damage to differ-
ent structures in the nephron and determining which lesions 
are primary is a major challenge (Fig. 1). However, there 
appears to be good evidence for early tubular involvement 
in the course of DKD and its role in the pathogenesis of both 
microalbuminuria and hyperfiltration.
The proximal tubule: a therapeutic target 
for nephro‑protection
In normoglycemic humans, the high-capacity cotransporter 
SGLT2 is responsible for some 97% of glucose reabsorption 
by the PT, and retrieves filtered glucose with sodium in a 
1:1 molar ratio; SGLT1 in the later part of the PT reabsorbs 
any remaining luminal glucose. The two basolateral glucose 
transporters, GLUT1 and GLUT2 can return reabsorbed glu-
cose to the bloodstream. Different structures within the PT 
co-operate to help to maintain the blood glucose level [34].
The glucose load in PT is increased with hyperglycemia 
in diabetes and exceeds the renal transport maximum for 
glucose, leading to glycosuria in poorly controlled DM. 
Blocking glucose reabsorption in the PT increases glucose 
excretion in the urine and can reduce high circulating blood 
glucose levels. Canagliflozin is an example of a SGLT2 
inhibitor that was approved by the Food and Drug Adminis-
tration (FDA) in 2013 as a new glucose-lowering medication 
for adults with type 2 diabetes.
Use of SGLT2 inhibitors has brought new insights into 
the complex mechanism of PT glucose reabsorption. Previ-
ously, only medication blocking RAS showed some nephro-
protective effects in patients with DM. New therapeutic 
strategies to improve renal outcome have been sought and in 
a recently published study Empagliflozin, another selective 
SGLT2 inhibitor, significantly (and unexpectedly) slowed 
progression of DKD and lowered the risk of clinically rel-
evant renal events in type 2 DM patients [35], as well as 
heart failure. This new class of drug appears very promising. 
In addition to the EMPA-REG study, there are several ongo-
ing studies looking at the effects of SGLT2 inhibition on 
cardiovascular and kidney outcomes, including DECLARE, 
CANVAS, and CREDENCE [36].
Why does targeting the SGLT2 cotransporter improve 
renal outcomes in addition to many metabolic and cardio-
vascular complications in DM? Current thinking is that the 
beneficial effect of SGLT2 inhibition is primarily a direct 
nephro-vascular effect [31]. Activation of TGF is a myogenic 
response to distal sodium delivery, inducing glomerular 
arteriolar vasoconstriction and reduction in GFR [31]. DM 
with hyperglycemia is associated with renal sodium reten-
tion and increased proximal tubular reabsorption, reducing 
distal delivery and decreasing TGF, and thus hyperfiltration 
[34]. Therefore, the beneficial renal effect of Empaglifozin 
highlighted in the EMPA-REG OUTCOME Trial is thought 
to be the consequence of reducing intraglomerular pressure 
and barotrauma to podocytes [31]. This mechanism may also 
underlie the associated decrease in urinary albumin excre-
tion seen with SGLT2 inhibition [37].
Despite the reduction in glomerular hyperfiltration and 
podocyte stress, SGLT2 inhibitors have other potentially 
nephro-protective mechanisms that may be renal or sys-
temic. Looking at the former, some important pathophysi-
ological changes in the nephron have been reported in rela-
tion to DM [34]:
Upregulation in renal SGLT2 expression has been dem-
onstrated in both human cells and some animal models 
of Type 1 and Type 2 DM [34]. It is still unclear whether 
this phenomenon is the result of hypertrophy of PT in 
DM and/or of an ‘energy/glucose saving’ response to a 
glucose sensor downstream of the early proximal tubule. 
This maladaptive process of SGLT2 upregulation helps 
to sustain high blood glucose. Therefore, targeting this 
upregulated cotransport specifically, means a better gly-
cosuric and blood glucose-lowering effect and, perhaps, 
also a prevention of glucose toxicity to PTEC [33].
Upregulation of SGLT2 has been demonstrated in both 
human and animal models of type 1 and type 2 DM, but 
what happens to SGLT1 activity is more controversial. 
Under high glucose conditions, SGLT1 expression has 
been reported to be increased, reduced or unchanged. 
In STZ-diabetic rats and in diabetic obese Zucker rats 
an increase in SGLT1 mRNA expression was docu-
mented, whereas in Akita mice models of type 1 DM, 
as well as in normoglycemic rats under pharmacologi-
cal or genetic SGLT2 inhibition, SGLT1 renal protein 
expression decreased. Thus, these animal studies show 
contrasting changes in SGLT1 levels in different rodent 
models of diabetes [38]. When SGLT2 function is satu-
rated by glucose overload due to DM or, alternatively, is 
inhibited pharmacologically or genetically, does SGLT1 
increase its activity to prevent a loss of glucose in the 
urine? Rieg et al. showed that with genetic or pharma-
cological inhibition of SGLT2 in non-diabetic mice, a 
compensatory increase in SGLT1-mediated transport 
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occurs, which explains why renal fractional glucose 
reabsorption is maintained at 40–50% [39]. Following 
this reasoning, Abdul-Ghani et al. [40] in 2013 suggested 
that SGLT2 inhibitors cause SGLT1 to reabsorb glucose 
at its maximum capacity, unmasking its global reabsorp-
tion reserve, in accordance with the results of Powell 
et al. [41]. The latter group demonstrated that in SGLT2 
knockout mice urine glucose excretion is approximately 
30% of filtered glucose. Consistent with this, observa-
tions in humans showed a fractional glucose reabsorption 
rate of about 40–50% following a maximal effective dose 
of SGLT2 inhibitor. A compensatory effect of SGLT1 is 
also supported by micropuncture studies along the late 
proximal tubule in Sglt2−/− mice [38]. Thus, there is 
an increase in glucose reabsorption mediated by SGLT1 
when the principal cotransporter (SGLT2) is function-
ally deleted. Therefore, when a compensatory increased 
activity of SGLT1 occurs in response to an excessive glu-
cose to be reabsorbed, one would expect an upregulation 
of this tubular transporter. However, in a genetic model 
of T1DM (Akita mice) and in response to SGLT2 gene 
knockout and pharmacological inhibition of SGLT2 in 
non-diabetic mice, SGLT1 protein expression was found 
to be reduced. How can this apparent discrepancy be 
explained? Downregulation of SGLT1 expression, would 
attenuate any increase in glucose reabsorption and pro-
mote glycosuria, which has been put forward as protective 
mechanism for the kidney. The late PT is highly vulner-
able to hypoxia and acute injury in general, and Vallon et 
al. proposed that downregulation of SGLT1 expression 
could mitigate or prevent glucose toxicity in this nephron 
segment [42].
Rat studies suggested the translocation of GLUT2 
from basolateral to apical brush border PT membrane 
in diabetes [43]. A similar mechanism occurs in the 
small intestine, where SGLT1 sensitivity is required for 
GLUT2 translocation. Does SGLT2 in the kidney play 
the same role of sensor that SGLT1 has in the small 
intestine to allow GLUT2 translocation? Furthermore, 
does the translocation occur even if SGLT2 is phar-
macologically inhibited? Moreover, it is still unknown 
whether the translocation of GLUT2 occurs in humans 
Fig. 1  Interactions between glomerulus and proximal tubule (PT) in the pathophysiology of microalbuminuria, hyperfiltration and proximal 
tubule glucose (GLU) reabsorption in the context of DKD
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and if a GLUT2 contribution in facilitating glucose 
reabsorption when PT lumen is exposed to high glucose 
concentration is physiologically relevant [34].
Recent evidence suggests a functional link between 
SGLT2 and the sodium–hydrogen exchanger (NHE) 3 
in that SGLT2 inhibition may also inhibit NHE3 in the 
proximal tubule. Taking all the evidence together, it is sug-
gested that the nephro-protective effects of SGLT2 inhibi-
tors are directly or indirectly related to decreased sodium 
reabsorption. However, an alternative explanation has been 
proposed [44]. Firstly, Wakisaka suggested that SGLT2 
inhibitors may increase sodium reabsorption in the proxi-
mal tubule [45], in contrast to the still widely accepted 
explanation for SGLT2 inhibition and nephro-protection. 
However, the reasoning is that in the course of SGLT2 
inhibition, SGLT1 has a greater role in glucose reabsorp-
tion with a glucose to sodium ratio of 1:2, rather than 1:1 
with SGLT2. Secondly, Wakisaka proposed that SGLT2 
inhibition and nephro-protection is not dependent entirely 
on TGF. In fact, in the 1990s the presence of SGLT2 and 
GLUT1 was also recognised in glomerular mesangial cells. 
Given that the loss of mesangial contractility is hypoth-
esized to be another potential mechanism for glomerular 
hyperfiltration, Wakisaka explored the effect of high glu-
cose concentration on mesangial cells. After incubation 
of rat mesangial cells for 6 days in 20 mM glucose, the 
contraction of mesangial cells in response to angiotensin 
II showed a decrease. This mechanism was ascribed to 
SGLT2 acting as a glucose sensor and sodium-calcium 
exchanger, because Phlorizin, a competitive inhibitor of 
SGLT1 and SGLT2, attenuated mesangial cell dysfunc-
tion, normalizing its contractile response [46]. The author 
concluded that the nephro-protective effect of SGLT2 inhi-
bition was partially driven by its direct cellular action on 
mesangial cells, offering a new perspective [45].
The kidney has a complex structure–function relationship 
and nephro-protection is likely to depend on several mecha-
nisms yet to be elucidated. In this sense, many pleiotropic 
effects of SGLT2 inhibition have been postulated. Given that 
the PT is an actively transporting segment of the nephron, 
with a high number of transporters requiring a continuous 
energy supply, and with a large number of mitochondria in 
PTECs, we should consider the ‘thrifty substrate hypoth-
esis’ in this context. According to this hypothesis, SGLT2 
inhibition through mild ketosis promotes β-hydroxybutyrate 
uptake in the myocardium and kidney. This substrate selec-
tion improves mitochondrial efficiency and ATP genera-
tion. In addition, the modest hemoconcentration that fol-
lows SGLT2 inhibitor treatment may increase tissue oxygen 
delivery [47]. Another mechanism that also might contribute 
to nephro-protection of SGLT2 inhibitors is the increased 
renal content of HIF1-α [42].
Is the downregulation of SGLT1 expression a further 
nephro-protective mechanism? Could the sodium-glucose 
cotransporter SGLT1 be a second renal therapeutic target in 
DKD? Although this has been considered, its main target, 
and potential source of benefit, would be inhibiting intes-
tinal absorption of glucose and postprandial excursions in 
blood glucose. How significant for nephro-protection is any 
effect on mesangial cells? Are there additional effects of 
SGLT2 inhibitors that explain the positive renal outcome 
in DM patients? Considering the evidence as a whole, renal 
glucose reabsorption is ‘dysregulated’ in DM and the data 
so far suggest that several mechanisms may underlie nephro-
protection by SGLT2 inhibitors. More studies are needed to 
understand better how the PT handles glucose in DM.
Diabetic tubulopathy: from pathophysiological 
mechanisms to histological data and evidence 
for a causative role for the renal tubule in DKD
The interplay of the glomerulus and proximal tubule in DKD 
has been described in the pathogenesis of proteinuria, hyper-
filtration and, importantly, nephro-protection. Nevertheless, 
there are findings that suggest a primary role for the PT 
in causing nephron injury and dysfunction, defined by the 
term ‘Diabetic Tubulopathy’ [48]. Because of their position 
and major reabsorptive role within the nephron, PTECs are 
exposed to factors in the glomerular filtrate, in the peritu-
bular capillary blood supply, and in the interstitium. Con-
sequently, they can be injured by a variety of potentially 
damaging agents that can trigger a pro-inflammatory and 
pro-fibrotic response causing tissue injury. In 1999, Gil-
bert and Cooper highlighted non-glomerular mechanisms 
involved in tubular cell damage in diabetes, emphasising that 
tubulo-interstitial injury was more than could be explained 
by glomerular injury alone [49].
The factors directly related to glucose metabolism, and 
potentially implicated in determining the pro-inflammatory 
and pro-fibrotic phenotype of the renal tubule in DKD, are a 
high glucose concentration and formation of advanced gly-
cosylation end-products (AGEs). A summary of the main 
mechanisms thought to be involved is shown in Table 2. 
Why are PTECs so vulnerable to glucose damage? PTECs 
are exposed to glucose apically from the filtered glucose load 
or basolaterally through elevated interstitial tissue concentra-
tions of glucose. PTECs cannot decrease glucose transport 
to prevent excessive changes in intracellular glucose when 
exposed to high glucose concentrations [50].
However, there are other stimuli, not strictly related to 
glucose control that may affect the proximal tubule, for 
example, activation of local vasoactive hormone systems 
that cause hemodynamic changes. Over-expression of 
endothelin [49] and local angiotensin II in the renal tubule, 
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activation of vascular endothelial growth factor (VEGF), and 
reduction of nitric oxide (NO) [52, 53] may cause vasocon-
striction of the afferent and efferent arterioles, as well as 
the interlobular arteries. The combination of several vascu-
lar and metabolic effects may induce ischemic damage to 
PTECs. This may cause elevated energy demand of tubules 
due to increased reabsorption of glucose, AGEs and pro-
teins, as well as reductions in peritubular blood flow with 
post-glomerular vasoconstriction and capillary loss follow-
ing tubulo-interstitial expansion [49]. In addition, elevated 
blood pressure, often associated with impaired glucose con-
trol, may induce mechanical stress in the peritubular capil-
lary network, which compared with the glomerulus is poorly 
adapted to cope with an increased blood pressure [49] and 
mechanical shear stress. All the changes in the vascular fac-
tors mentioned above can lower post-glomerular blood flow 
in diabetes and contribute to further reductions in oxygen 
delivery to the tubules and hypoxia.
As well as hemodynamic changes, other pathways are 
likely to contribute to the pathogenesis of tubular damage 
in DKD. Purinergic signalling may be involved, since it has 
been shown that this pathway is part of an inflammatory 
cascade and can lead to renal glomerular, tubular and vascu-
lar cell damage in a variety of inflammatory renal diseases, 
including DKD. Local productions of chemokines, adhesion 
molecules, and inflammatory cytokines are upregulated by 
chronic stimulation from hyperglycemia and other modula-
tors [54]. In type 2 diabetic patients with nephropathy, tubu-
lar P2X4R (P2X4R purinoreceptor) expression is upregu-
lated and closely related to NLRP3 inflammasome activation 
and renal interstitial inflammation [55].
Recent studies have also shown the importance of the 
endocannabinoid system in normal PTC function. In the 
model of Jenkin et al., increased circulating endocannabi-
noids in DM modify the expression of cannabinoid receptors 
in PTECs that might participate in activation of inflamma-
tion and cell hypertrophy, as well as in tubular cell dys-
function [56]. In DKD, the purinergic and endocannabinoid 
systems deserve further investigation as potential targets 
for therapeutic intervention. Finally, there are a number of 
pro-inflammatory factors abnormally filtered by altered glo-
meruli in the course of diabetes that could disrupt PTEC 
function, including IL-6, Il-8, IL-1β, ROS, MCP-1 and 
RANTES [57].
Given the uncertainty and speculation over its pathogen-
esis, is diabetic tubulopathy a real entity in DKD and does 
it have any implications for treatment? A close correlation 
between the extent of tubulo-interstitial injury and long-term 
renal function in a variety of primary glomerular diseases 
has been demonstrated [49]. Furthermore, the extent of renal 
dysfunction is generally poorly associated with changes in 
glomerular morphology, whereas it correlates well with 
chronic tubulo-interstitial injury [48]. A recent review of 
the histological changes in early DKD described tubular cell 
hypertrophy, thickening of the tubular basement membrane, 
and interstitial inflammation with mononuclear cell infiltra-
tion. Progression of these early tubular abnormalities leads 
to interstitial fibrosis and tubular atrophy (IFTA) [58].
Brito et al. reported that in T1DM, the tubular cell base-
ment membrane (TBM) width showed a strong correlation 
with glomerular basement membrane (GBM) width and 
mesangial expansion, the two most important and char-
acteristic findings in the glomeruli of DKD. In the same 
report, TBM and GBM width were more closely correlated 
with glycosylated haemoglobin than other renal structural 
measures [59]. Moreover, the first measurable change, GBM 
thickening, has been detected very early in the course of 
DKD within 1.5 to 2.5 years after onset. Therefore, the par-
allel change in TBM may also occur very early and is a 
primary abnormality, and it is not secondary to glomerular 
hemodynamic changes [60].
Furthermore, early changes have been found in the PT in 
the rat model of Streptozotocin-induced diabetes: an early 
hyperplastic phase, followed by either transition to hyper-
trophy or cellular senescence. An accelerated senescent 
phenotype was also found in tubular cells of T2DM patients 
with nephropathy [61]. PTECs show increased lipofuscin 
pigment and vacuolarization, perhaps due to a high tubular 
lysosomal load and cell adaptation to stressful stimuli such 
as hyperglycemia, glycogen accumulation and subnuclear 
lipid vacuolarization [58].
In the later stages of DKD in both T1DM and T2DM 
patients, abnormalities involving the glomerulotubular 
junction have been described, with a glomerulus without 
a tubular attachment and known as an ‘atubular glomeru-
lus’ (AG), which is non-functioning, or an atrophic tubule 
[60]. Najafian et al. showed that the fractional volume of 
atrophic tubules, percent of atubular glomeruli, and percent 
of glomeruli with tip lesions accounted for 94% of the GFR 
variability in diabetic patients, highlighting the importance 
of AG and glomerulotubular junction abnormalities in the 
development and progression of DN [62].
Tubular biomarkers: use in clinical care
The significant incidence and prevalence of DKD across 
diabetic populations and the limitations of microalbumi-
nuria have emerged recently. Novel and better biomarkers 
for clinical diagnosis and management of DKD are needed 
to provide earlier diagnosis and more accurate prognosis. 
Microalbuminuria does still have a useful role in screen-
ing diabetic patients for DKD. It has several advantages: 
it is organ specific and a marker of generalized endothe-
lial dysfunction with important prognostic implications for 
cardiovascular and renal outcomes [63], and measurements 
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are widely available. It also reflects glomerular injury, as 
well as tubular dysfunction. However, its evolution is not 
predictable: microalbuminuria can regress towards normal 
values, progress towards macroalbuminuria, or remain sta-
ble for many years [64]. Moreover, there is evidence that 
DKD can develop with normoalbuminuria, and even though 
microalbuminuria is currently first-line screening for kidney 
involvement in DM, structural changes may appear in the 
glomerulus before it develops [65].
To overcome the limitations of microalbuminuria, new 
biomarkers in DKD are being sought. A clinically useful 
biomarker needs to be detectable early in the pathophysi-
ological process of a disease, to have high sensitivity and 
specificity, and to provide high diagnostic and prognos-
tic values. There are several novel and promising urinary 
biomarkers for renal damage in the early stages of DKD 
[64–66]. Urinary biomarkers in DKD can indicate the site of 
damage in the nephron, impaired function of the nephron, or 
the underlying pathophysiological process. We summarize 
these urinary biomarkers in DKD in Fig. 2, which outlines 
the principal tubular biomarkers that could be helpful in 
early detection of DKD.
What measurements are appropriate for detecting PT 
dysfunction in DKD? There are both functional and struc-
tural markers. One approach is to evaluate PT dysfunction 
by assessing impaired reabsorption of filtered proteins. The 
major site for filtered protein reabsorption is in the PT and 
assuming no significant post-glomerular degradation or 
secretion of these proteins, theoretically the more freely 
filtered the protein is, the greater should be the increment 
Table 2  Mechanisms of damage due to high glucose concentration and advanced glycosylation end-products (AGEs) on the renal tubule in dia-
betes mellitus
Proximal tubule (PT) Transforming growth factor beta (TGF β), Angiotensin II receptor type 1 (AT1), Vascular endothelial growth fac-
tor (VEGF), chemokine (C-C motif) ligand 2 (CCL-2), Mitogen-activated protein kinase (MAPK), Protein kinase C (PKC), Toll like receptor 
(TLR), Macrophage Inflammatory Protein-3 MIP-3α, Krueppel-like factor 6 (KLF6), serum and glucocorticoid-regulated kinase 1 (SGK-1), 
Hypoxia-inducible factors (HIF), Intercellular Adhesion Molecule 1(ICAM- 1), Signal transducer and activator of transcription 1 (STAT- 1), 
connective tissue growth factor (CTGF)
Stimulus Injury pathway Effects on proximal tubule
High glucose Increased expression of the pro-fibrotic cytokine TGF-β Production of collagens type I and type IV with autocrine 
and paracrine effects on interstitial cells [49]
Acceleration of polyol pathway metabolism and accumu-
lation of sorbitol
Stimulation of extracellular matrix expression [49]
Increased glucose uptake induces angiotensin II, TGF-β 
and cyclin-dependent kinase inhibitors
Cell cycle arrest and a switch to tubular hypertrophy and a 
senescence-like phenotype [51]
Promotion of angiotensinogen and AT1 expression Increased TGF β1 expression and PTECs hypetrophy oxida-
tive stress [49]
Production of VEGF, TGF β, IL-6, CCL-2 partly through 
MAPK, PKC signalling, TLR
Neo-angiogenic, pro-fibrotic and pro-inflammatory PTECs 
shift [48]
Upregulation of MIP-3α Intracellular oxidative stress [48]
KLF6 over-expression and activation of p38 signaling and 
activator protein-1
Promotion of epithelial mesenchymal transition [48]
Generation of intracellular (mitochondrial) ROS Reduction of NO and vasoconstriction of peritubular 
vessels. Pro-inflammatory gene upregulation. Oxidative 
stress [52]
SGK-1 overexpression Increased proximal tubular cell growth, progression through 
the cell cycle, and inhibited apoptosis [50]
Inhibition of hypoxia-induced activation of HIF and 
VEGF expression
Reduced protection of hypoxic tissues [50]
Advanced glycosyla-
tion end-products 
(AGEs)
Activation of intracellular second messenger mitogenic 
activated protein kinase
Increased TGF β1 expression [49]
Increased in cytosolic phospholipase A2 α activity and 
cellular phosphoinositol 4,5 bisphosphate production
Generation of intracellular ROS and Oxidative stress [52]
Increased circulation and therefore increased catabolism. 
Increased PT AGE binding→ Stimulation of IL-8 and 
ICAM-1 expression via NF-κB, MAPK- and STAT-
1-dependent pathways and TBM glycation
Infiltration of Leukocytes [48]
Upregulation of tubular expression of CTGF, TGF β, 
VEGF. Stimulated expression of IL-6 and CCL-2. 
Activation of NF-κB
Neoangiogenetic, profibrotic and proinflammatory PTEC 
shift [51]
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in urinary excretion when the tubular reuptake process is 
disrupted. In this category of ‘Functional Tubular Biomark-
ers’ (FTB) are included plasma proteins of low molecular 
weight (LMWP) that are freely filtered by the glomerulus 
and almost fully reabsorbed by the PT. Another approach is 
to identify those substances excreted in urine as a result of 
tubular damage or regeneration. These ‘Structural Tubular 
Biomarkers’ (STB) are urinary enzymes that originate not 
from plasma, but directly from tubular cells.
In ‘tubular’ proteinuria, PT endocytic function is impaired 
and large amounts of LMWP appear in the urine, for exam-
ple, UfRBP4 is elevated some 1,000-fold when endocytic 
function is completely abolished, as occurs in a number of 
monogenic tubular diseases [18]. The conventional expla-
nation for increased excretion of LMWP is tubular disease. 
However, there is another possible mechanism of increased 
LMWP excretion in DM. There is evidence from at least 
one animal model that proteins compete for reabsorption 
by the proximal tubule [67]. There is also clinical evidence 
that the same pathway is used for uptake of filtered albu-
min and LMWP in humans, suggesting that two or more 
proteins might compete for reabsorption [68]. This would 
have the effect of increasing the excretion of a freely filtered 
plasma protein as a result of increased filtration of other 
proteins, such as albumin. This might occur when the size 
and charge permselectivity of the glomerulus is impaired 
in DKD. However, even early glomerular disease and loss 
of size and charge permselectivity in DM with increased 
albumin leakage may not cause microalbuminuria, if normal 
tubular function can reabsorb the excess albumin from the 
glomerular filtrate. The reserve capacity for protein uptake 
by the proximal tubule is unknown, but it is likely that the 
tubule has some reserve capacity for reabsorption; however, 
competition for reuptake between albumin and LMWP, as 
discussed earlier, may occur. Consequently, small increases 
in albumin leakage across the glomerulus in early DM 
may not cause ‘microalbuminuria’, but would be detected 
indirectly by measurement of increased LMWP excretion. 
Others have also proposed dissociation between increased 
glomerular leakage of albumin and microalbuminuria [22]. 
A possible limitation of the use of functional tubule bio-
markers is an altered level in the serum (plasma overload) 
and/or alteration of glomerular filtration rate.
Fig. 2  Classification of urinary biomarkers in diabetic kidney disease [64–66]. *Tubular biomarker further discussed in the text
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The principal tubular biomarkers in DKD are briefly 
described in Table 3. The major strengths of several of them 
are [64–66]:
• a good correlation between the degree of damage at tub-
ulo-interstitial level and the deterioration of renal func-
tion
• an early detection of tubule damage in the course of DKD
• tubular involvement in both T1DM and T2DM
• presence in normoalbuminuric patients
• a correlation with duration, severity and control of DM
• a progressive increase in patients with micro and mac-
roalbuminuria.
The main limitation of tubular biomarkers is their poor 
independent predictive value for GFR decline and develop-
ment of albuminuria, although there are conflicting findings 
in relation to their predictive value. One study assessed two 
tubular damage biomarkers, N-acetyl-β-D glucosaminidase 
(NAG) and β2 microglobulin. They did not add any prog-
nostic benefit in detecting progressive renal impairment 
defined as a decline in eGFR of ≥50% from baseline, or 
start of dialysis, in T2DM, whereas histological findings of 
tubular atrophy and interstitial fibrosis (IFTA) did; although 
both NAG and β2 microglobulin significantly correlated with 
the severity of tubulo-interstitial lesions. In fact, the IFTA 
scores were good predictors of renal prognosis, independent 
of other indicators of progression [70]. However, this was 
a retrospective analysis of over 25 years and over such a 
long period it is likely that both the sensitivity and accuracy 
of biomarker measurements have changed, as well as clini-
cal care. A 3-year prospective intervention trial by Nielsen 
et al. found that T1DM patients with high levels of urinary 
NGAL and KIM-1 had a faster decline in GFR, suggest-
ing that tubular damage is important for progression, even 
though the markers did not add to other markers of likely 
progression [71]. A limitation of this study was the stor-
age of samples at only −20 °C for 10 years before analy-
sis. Tubular biomarkers are sensitive to their handling and 
storage conditions, and even −70 °C can degrade over sev-
eral years [72]. In a study by Conway et al. uKIM-1/Cr and 
uGpnmb/Cr ratios were elevated in patients with incipient 
DN due to T2DM, suggesting an ongoing tubular injury. 
Both tubular biomarkers were correlated with the severity 
of proteinuria and with a faster decline in renal function. 
Nonetheless, neither uKIM-1/Cr nor uGpnmb/Cr ratio added 
significant prognostic value to ACR alone in a 4-year-follow 
up. Perhaps in can take many years before low-grade tubular 
injury translates to a decline in eGFR [73].
Nevertheless, there are other studies reporting that some 
tubular biomarkers do have a role in predicting the evolu-
tion of DKD. In 2010, Kern et al. showed that the baseline 
excretion of NAG and its increase over time independently 
predicted both micro- and macroalbuminuria in T1DM 
patients [74]. In 2011 Fu et al. in a study of T2DM patients 
and healthy controls showed that NGAL increased signifi-
cantly across the four groups from controls to normoalbu-
minuric, microalbuminuric and macroalbuminuric patients. 
In addition, NGAL as well as NAG, correlated with the 
urinary albumin-creatinine ratio (UACR) in the normoal-
buminuric group, potentially predicting microalbuminuria 
and demonstrating a negative correlation with eGFR in the 
macroalbuminuria group. Furthermore, recent studies have 
explored the predictive value of tubular biomarkers in DKD 
[75]. In 2012, Soggiu et al. demonstrated increased retinol 
-binding protein 4 (RBP4) and α1-microglobulin in micro-
albuminuric patients. These results also showed a positive 
correlation between increases of LMWP and albuminuria. 
Thus, increased excretion of RBP4 and α1-microglobulin 
could be predictive of early-stage nephropathy in T1DM 
[76]. Recently, Panduru et al. showed that in a large cohort 
of patients with T1DM with a median follow up of 5.8 years, 
Liver-Type Fatty Acid Binding Protein (L-FABP) was an 
independent predictor of DKD evolution as assessed by pro-
gression from normo- to microalbuminuria, from microalbu-
minuria to macroalbuminuria, and from macroalbuminuria 
to ESRD [77]. A Korean group has also published results of 
237 T2DM patients enrolled from May 2008 to December 
2009, followed annually until March 2012 and screened for 
Cystatin C and non-albumin protein (NAP). Both measure-
ments were significantly associated with a decline in eGFR 
after adjusting for age and several clinical confounders [78].
To clarify their utility in the clinical context of DM 
patients, longitudinal and prospective studies of biomark-
ers are needed, starting at an early phase of the disease. 
Given the instability of most proteins in urine, careful 
measures to reduce pre-analytical variations are critical 
for reliable results.
Finally, there is growing evidence for the potential of 
both proteomics and microRNA (miRNA) profiling to find 
new biomarkers for DKD. Although, it is not the aim of 
the present review, these two novel-approaches to discover 
new biomarkers are briefly considered in the context of 
DKD biomarker discovery. Essentially, both proteomic and 
miRNA approaches can explore DKD in a more dynamic 
and cross-sectional way that can consider structural, func-
tional and pathophysiological pathways within the nephron 
as a continuum (Fig. 3).
Proteomic methods might provide a more dynamic phe-
notypic profile of the function and dysfunction of kidney 
cells, reflecting the complexity and pathophysiological 
changes at different stages of DKD. This methods may 
provide new insights into the pathogenesis of progression 
of DKD and might become early diagnostic biomark-
ers, specifically providing some functional or causative 
insights or associative patterns of markers (e.g. CKD273 
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Table 3  Principal structural and functional tubular biomarkers over-
expressed in the urine and explored in clinical background of diabetic 
kidney disease [18, 64–66, 69]. Proteins of Low Molecular Weight 
(LMWP), Proximal tubule (PT), Proximal Tubule Epithelial Cells 
(PTECs), Molecular weight (MW), brush border (BB)
Functional tubular biomarkers (FTB)
 Retinol-binding protein 4 LMWP (~21 kDa when not bound to transthyretin), freely filtered by the 
glomerulus and almost completely reabsorbed in the PT. No tubular secre-
tion. Measurement of free form of uRBP4 performs significantly better than 
previous measurement of total uRBP4 in the discrimination of patients with 
proximal renal tubular disorders
 Cystatin C Cysteine protease inhibitor with MW 13 kDa freely filtered by the glomerulus 
and almost entirely reabsorbed in the PT. No tubular secretion
 α1-microglobulin Glycoprotein with MW 26–31 kDa. The unbound form is filtered freely 
through the renal glomerular basement membrane and is reabsorbed by the 
PTECs. No tubular secretion
 β2-microglobulin LMWP (11.8 kDa) filtered by the glomerulus and is degradated in the PT via a 
megalin-dependent pathway. Unstable in urine
 Albumin Molecular weight of 65 kDa; normally very little is filtered at the glomerulus. 
With glomerular barrier damage, filtration occurs and is followed by tubular 
reabsorption; the resulting albuminuria reflects the combined contribution of 
these two processes. Reserve capacity for reabsorption by PT is unknown
Structural tubular biomarkers (STB)
 Neutrophil gelatinase-associated lipocalin (NGAL) A 25 kDa protein covalently bound to gelatinase from human neutrophils and 
part of the lipocalin family. NGAL is hyper-produced in the kidney tubules 
within a few hours after insults such as ischemia–reperfusion. It is freely 
filtered and reabsorbed in PT. Although it can be regarded as both FTB and 
STB, it is mainly considered a STB
 Kidney injury molecule-1 (KIM-1) A type 1 transmembrane protein expressed on the apical membrane of PT 
cells. Its ectodomain is cleaved and released into the lumen of the tubule 
and ultimately appears in the urine. KIM-1 facilitates repair of the damage 
by removing cellular debris and apoptotic bodies from the injured tubulo-
interstitial compartment. Elevated in acute kidney damage
 N-acetyl-β-D glucosaminidase (NAG) Lysosomal brush border enzyme found in the PT cells. Because of its rela-
tively high molecular weight (>130 kDa), plasma NAG is not filtered though 
the glomeruli. NAG is released into the urine after renal tubule injury
 Liver-type fatty acid binding protein (L-FABP) Intracellular carrier protein expressed in the cytoplasm of human PT cells. 
MW: 14.2 kDa. Believed to have protective functions. Its excretion is associ-
ated with structural and functional tubular damage. Moreover, it is freely 
filtered and reabsorbed in PT. Although it can be regarded as both FTB and 
STB, it is mainly considered as a STB
 Cubilin and Megalin Two apical membrane receptors responsible for endocytosis via clathrin-
coated vesicles, the central mechanism for protein reabsorption in the PT. 
Megalin is an approximately 600 kDa transmembrane protein belonging 
to the LDL receptor family, and Cubilin is a slightly smaller peripheral 
membrane protein, approximately 460 kDa. Most proteins filtered through 
glomeruli have been identified as ligands of megalin, cubilin, or both
 Alkaline phosphatase (ALP) and γ-Glutamyltransferase (GGT) ALP is an enzyme with an MW 70–120 kDa. It is associated with the mem-
branes of cell surfaces located in the PT, especially in the BB of epithelial 
cells. It originates from damaged renal tubules, and its levels are associated 
with the degree of damage. GGT is an enzyme with a molecular weight 
~90 kDa. It is present in the PT and the increased GGT excretion in the urine 
reflects the damage of the BB membrane and the loss of microvilli. The 
urinary levels of these enzymes/proteins are not influenced by their plasma 
levels
 Glycoprotein non-metastatic melanoma B (Gpnmb) A transmembrane glycoprotein expressed on renal tubular cells. Increased 
during repair after renal ischemia—reperfusion injury. It may be a marker 
of tubular regeneration. Elevated in proteinuric renal diseases including 
diabetic nephropathy
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[79]) with reliable prognostic value in the clinical setting 
[80], but as yet it has not been able to replace albuminuria.
It has been shown that miRNAs, noncoding RNA single-
stranded molecules, are found ubiquitously in body fluids 
(circulating miRNAs, urinary miRNAs, miRNAs have been 
found also in saliva, breast milk, cerebrospinal fluid) and 
that their dysregulation is closely linked to altered expres-
sion of regulatory proteins in many diseases. Interestingly, 
they have several intriguing features that make them suitable 
for being considered ideal biomarkers in many clinical set-
tings. Abundantly expressed in cells, miRNAs can be tis-
sue- and disease-specific markers. They are more resistant to 
degradation than proteins and mRNA. This feature has value 
in kidney diseases where urine has been one of the widely 
used sources of biomarkers, even though it can be an unsta-
ble milieu. The high stability under extreme handling and 
storage conditions of miRNAs may overcome this drawback 
and encourage the discovery of novel urinary biomarkers 
in kidney disease. MicroRNAs have been demonstrated to 
be a useful biomarker of kidney damage in both acute and 
chronic situations, such as acute kidney injury, various forms 
of chronic kidney disease, acute allograft rejection, and in 
chronic allograft dysfunction [81].
Current knowledge in the context of DKD seems to 
show that they can reflect fibrogenesis and expansion of the 
mesangial extracellular matrix [82]. In a study published in 
2015, Argyropoulos et al. investigated the urine profile of 
T1DM patients still in a normoalbuminuric phase by com-
paring individuals who developed signs of nephropathy over 
an 18-year follow-up with those who did not. The results 
showed that miRNA profiles were different between the two 
groups long before some of them evolved from normo- to 
microalbuminuria [83], highlighting that changes in miRNA 
profiles are associated with different stages of DKD. The 
predicted target of differentially expressed miRNAs can 
map to specific pathways thought to be responsible for the 
development of progressive DKD, e.g., collagen produc-
tion, inflammation, innate immunity, toll-like receptor sig-
nalling and neovascularization, supporting data for a role 
of miRNAs in regulating several functions and as potential 
therapeutic targets. In a later study using urinary exosomes, 
rather than cell-free circulating miRNAs, Delić et al. found 
that miRNA expression was altered among T2DM patients 
with nephropathy compared with T2DM patients without 
nephropathy, and healthy controls [84]. However, the pat-
tern of miRNAs was different compared with that found in 
T1DM, and neither study revealed up-regulation of miR-192 
expression, one of the most well studied miRNAs in DKD 
associated with increased renal fibrosis.
Given the gender-related differences in miRNAs found 
in T1DM patients [83], the different miRNAs expressed 
in T1 and T2DM, and the often inconsistent results using 
different sources of miRNAs (i.e. renal tissue, free urinary 
miRNAs or urinary exosomes), further studies are needed to 
fully understand and optimize their potential role in clinical 
practice.
Conclusion
We have explored the evidence for the contribution of the 
renal tubule to DKD. Diabetic tubulopathy is a real entity 
and although closely associated with glomerular damage, it 
may have a separate pathophysiology. Different metabolic 
and non-metabolic factors impair tubular function and prob-
ably determine some specific histological tubular changes in 
early and late stages of DKD. The limitations of microalbu-
minuria as an early and predictive biomarker of DKD still 
need to be overcome through the discovery and clinical eval-
uation of new functional or structural tubular biomarkers.
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